Protirelin: Uses, Evidence, and Clinical Trial Data

Anyone looking into protirelin usually wants to know what it actually does in the body and how much research backs its use. Here is a plain-language summary based on available label and trial data.

Key takeaways

• Protirelin has a chemical identity catalogued under PubChem CID 638678, with molecular formula C16H22N6O4.
• No FDA label indication, mechanism, or pharmacologic class data was available for this summary.
• At least 21 clinical trials have been registered involving protirelin.
• Sampled trials span neuroendocrine research, spinocerebellar degeneration, and preterm labor studies.
• No FAERS adverse event reports were available in this dataset.

What the evidence shows

Clinical trial registries list at least 21 studies involving protirelin. Among the sampled trials, a Phase II double blind comparative study evaluated protirelin (as KPS-0373) in patients with spinocerebellar degeneration and reached completed status. A separate completed study examined antenatal thyrotropin-releasing hormone in women in premature labor to assess effects on lung disease in preterm infants. A third trial, focused on neuroendocrine mapping of the cerebral cortex, was withdrawn.

These sampled studies illustrate the range of contexts in which protirelin has been investigated, from neuroendocrine research to obstetric and neurological applications. No further label-based indication or mechanism detail was available to summarize here.